FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2690578590> ?p ?o ?g. }

• W2690578590 endingPage "2046" @default.
• W2690578590 startingPage "2046" @default.
• W2690578590 abstract "Abstract Introduction Chronic lymphocytic leukemia (CLL) is one of the most common B cell malignancies in the western world. The importance of B cell receptor (BCR) signaling in CLL pathology has led to the emergence of a number of targeted therapies specific to kinases in this pathway. Ibrutinib, a potent irreversible Bruton's Tyrosine Kinase (BTK) inhibitor, is highly effective in CLL with minimal side effects. However, resistance to Ibrutinib is now emerging among patients in several clinical trials. Aims/Methods To understand the molecular mechanisms underlying ibrutinib resistance to aid in early detection of resistant clones and to inform further treatment choices, we have developed an in vitro ibrutinib resistant model using BCR signalling dependent B cell lymphoma lines (Ramos and Namalwa). These cells have been conditioned by exposure to escalating doses of ibrutinib - starting from 0.001μM and increased over time to a lethal dose of 0.5μM in order to select drug-resistant cells. Single cell clones have been isolated from both the naïve and the resistant cells. The growth kinetics of 7 Ramos and 5 Namalwa resistant clones has reached the same pattern as the parental cells. Additionally, 3 naïve clones were isolated from each sensitive parental cell line. Dysregulation of the BCR signaling pathway was characterized by both flow cytometry, using specific anti-phosphokinase antibodies, and by Western blotting. In addition, RNA from these clones was isolated and analyzed on an Affymetrix HTA2.0 gene expression array (n=6 from two cell lines paralleled to one naïve clone from each cell line). Results In Ramos (n=3), gene expression profiling revealed significant upregulation of BCL2 and interferon response genes including interferon gamma (IFNG). However, in Namalwa (n=3), in addition to BCL2 upregulation, the expression arrays showed the overexpression of BCR signaling pathway genes including BTK itself, CD79B, LCK and GAB2 (Growth factor receptor-bound protein 2- associated-binder 2), suggesting hyper-activation of BCR pathway and constitutive activation of BTK and downstream kinases. Moreover, initial screening showed that not all of the resistant clones behave similarly. In Ramos, one clone apparently escapes ibrutinib inhibition by modifying different pathways compared to the other analysed clones, suggesting the potential for multiple mechanisms by which the malignant B cell clones can evade the toxic activity of targeted therapy. Results of this analysis were validated by qPCR and additional resistant clones were tested for BCL2 and IFNG expression. In Ramos, 7 resistant clones showed significant upregulation of BCL2 (mean 9.7-fold increase, range 2.1- 31.8, SEM 4.5) and IFNG(mean increase 8.3, range 2.6-19.1, SEM 2.2). IFNγ, is a known immune modulator linked to various stress signals indicating one possible resistance mechanism of malignant cells to anti-cancer therapies. In Namalwa, qPCR of 5 resistant clones showed significant upregulation of BTK (mean increase 10.3, range 2- 31: SEM: 5.4) and confirmed at the protein expression level by Western blotting as well; where the resistant cells over-express BTK protein compared to their respective naïve cells (n=6, mean increase 1.6, range 1.1- 1.9, SEM 0.16). Moreover, CD79B was over-expressed (mean over-expression 12.4, range 1.5- 22.2, SEM: 4.3) and 6-fold overexpression of LCK (mean increase 6, range 3.1- 9.5, SEM: 1.4) compared to the analysed naïve clones. Furthermore, validation with qPCR showed 12-fold upregulation of the GAB2gene (mean upregulation 12.7, SEM: 4.8), an adaptor protein which transmits crucial signals to activate downstream PI3K signaling with links to leukemogenesis. Conclusion Our results demonstrate that common mechanisms of resistance to BCR inhibition include both the up-regulation of B-cell receptor signaling activity and the up-regulation of anti-apoptotic molecules, particularly BCL2. More potent and more target-specific BTK inhibitors may overcome the hyperactivity of the BCR pathway. In contrast, inhibition of BCL2 with venetoclax may be beneficial in overcoming the emergent resistance to ibrutinib as these cells become more sensitive to BCL2 inhibition. These initial results support the combination of ibrutinib with the pro-apoptotic BCL2 inhibitor, venetoclax, which we are currently studying in the Bloodwise TAP CLARITY study. Disclosures Hillmen: Pharmacyclics: Research Funding; Janssen: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Abbvie: Research Funding." @default.
• W2690578590 created "2017-06-30" @default.
• W2690578590 creator A5022334281 @default.
• W2690578590 creator A5023756335 @default.
• W2690578590 creator A5035173394 @default.
• W2690578590 creator A5040002106 @default.
• W2690578590 creator A5047631289 @default.
• W2690578590 creator A5072919037 @default.
• W2690578590 creator A5084724295 @default.
• W2690578590 date "2016-12-02" @default.
• W2690578590 modified "2023-10-16" @default.
• W2690578590 title "Molecular Mechanisms of Ibrutinib Resistance: Defining a Logical Approach to Improving Targeted Therapy in CLL" @default.
• W2690578590 doi "https://doi.org/10.1182/blood.v128.22.2046.2046" @default.
• W2690578590 hasPublicationYear "2016" @default.
• W2690578590 type Work @default.
• W2690578590 sameAs 2690578590 @default.
• W2690578590 citedByCount "3" @default.
• W2690578590 countsByYear W26905785902017 @default.
• W2690578590 countsByYear W26905785902018 @default.
• W2690578590 countsByYear W26905785902020 @default.
• W2690578590 crossrefType "journal-article" @default.
• W2690578590 hasAuthorship W2690578590A5022334281 @default.
• W2690578590 hasAuthorship W2690578590A5023756335 @default.
• W2690578590 hasAuthorship W2690578590A5035173394 @default.
• W2690578590 hasAuthorship W2690578590A5040002106 @default.
• W2690578590 hasAuthorship W2690578590A5047631289 @default.
• W2690578590 hasAuthorship W2690578590A5072919037 @default.
• W2690578590 hasAuthorship W2690578590A5084724295 @default.
• W2690578590 hasConcept C157695867 @default.
• W2690578590 hasConcept C159654299 @default.
• W2690578590 hasConcept C170493617 @default.
• W2690578590 hasConcept C203014093 @default.
• W2690578590 hasConcept C2777938653 @default.
• W2690578590 hasConcept C2778453870 @default.
• W2690578590 hasConcept C2778461978 @default.
• W2690578590 hasConcept C2779878957 @default.
• W2690578590 hasConcept C42362537 @default.
• W2690578590 hasConcept C43907098 @default.
• W2690578590 hasConcept C502942594 @default.
• W2690578590 hasConcept C54355233 @default.
• W2690578590 hasConcept C62478195 @default.
• W2690578590 hasConcept C86803240 @default.
• W2690578590 hasConcept C90059517 @default.
• W2690578590 hasConcept C95444343 @default.
• W2690578590 hasConceptScore W2690578590C157695867 @default.
• W2690578590 hasConceptScore W2690578590C159654299 @default.
• W2690578590 hasConceptScore W2690578590C170493617 @default.
• W2690578590 hasConceptScore W2690578590C203014093 @default.
• W2690578590 hasConceptScore W2690578590C2777938653 @default.
• W2690578590 hasConceptScore W2690578590C2778453870 @default.
• W2690578590 hasConceptScore W2690578590C2778461978 @default.
• W2690578590 hasConceptScore W2690578590C2779878957 @default.
• W2690578590 hasConceptScore W2690578590C42362537 @default.
• W2690578590 hasConceptScore W2690578590C43907098 @default.
• W2690578590 hasConceptScore W2690578590C502942594 @default.
• W2690578590 hasConceptScore W2690578590C54355233 @default.
• W2690578590 hasConceptScore W2690578590C62478195 @default.
• W2690578590 hasConceptScore W2690578590C86803240 @default.
• W2690578590 hasConceptScore W2690578590C90059517 @default.
• W2690578590 hasConceptScore W2690578590C95444343 @default.
• W2690578590 hasIssue "22" @default.
• W2690578590 hasLocation W26905785901 @default.
• W2690578590 hasOpenAccess W2690578590 @default.
• W2690578590 hasPrimaryLocation W26905785901 @default.
• W2690578590 hasRelatedWork W1993345471 @default.
• W2690578590 hasRelatedWork W2154945466 @default.
• W2690578590 hasRelatedWork W2172629347 @default.
• W2690578590 hasRelatedWork W2767548364 @default.
• W2690578590 hasRelatedWork W2791299132 @default.
• W2690578590 hasRelatedWork W3010122964 @default.
• W2690578590 hasRelatedWork W3184389017 @default.
• W2690578590 hasRelatedWork W4282939855 @default.
• W2690578590 hasRelatedWork W4375865384 @default.
• W2690578590 hasRelatedWork W2475047365 @default.
• W2690578590 hasVolume "128" @default.
• W2690578590 isParatext "false" @default.
• W2690578590 isRetracted "false" @default.
• W2690578590 magId "2690578590" @default.
• W2690578590 workType "article" @default.